Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance

BACKGROUND: Evidence suggests that the PPARγ-agonist insulin sensitizer pioglitazone, may provide potential beneficial cardiovascular (CV) effects beyond its anti-hyperglycaemic function. A reduced endothelial progenitor cell (EPC) number is associated with impaired glucose tolerance (IGT) or diabet...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Spigoni, Valentina, Picconi, Angela, Cito, Monia, Ridolfi, Valentina, Bonomini, Sabrina, Casali, Chiara, Zavaroni, Ivana, Gnudi, Luigi, Metra, Marco, Dei Cas, Alessandra
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2012
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3489677/
https://ncbi.nlm.nih.gov/pubmed/23139771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0048283
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky